In vivo Proton Magnetic Resonance Spectroscopy of diseased prostate: Spectroscopic features of malignant versus benign pathology

Magnetic Resonance Imaging

Volumn 17, Issue 5, 1999, Pages 755-765

  Garcia Segura J M ^a,b   Sanchez Chapado M ^c   Ibarburen, C ^b   Viano J ^b   Angulo, J C ^c   Gonzalez J ^d   Rodriguez Vallejo J M ^d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b RM Nuestra Señora del Rosario ^*  (Spain)

^c Division of Urology   (Spain)

^d Medical affairs Merck sharp and Dohme ltd   (Spain)

Author keywords

Benign prostatic hyperplasia; Magnetic resonance spectroscopy; Non invasive diagnosis; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROTON NUCLEAR MAGNETIC RESONANCE;

AGED; AGED, 80 AND OVER; CHOLINE; CITRIC ACID; CREATINE; DIAGNOSIS, DIFFERENTIAL; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SIGNAL PROCESSING, COMPUTER-ASSISTED; STATISTICS, NONPARAMETRIC;

ILEX COOKII;

EID: 0345189502     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0730-725X(99)00006-5     Document Type: Article

References (41)

1. Oberhaensli R.D., Hilton-Jones D., Bore P.J., Hands L.J., Rampling R.P., Radda G.K. Biochemical investigation of human tumors in vivo with phosphorus-31 magnetic resonance spectroscopy. Lancet. 2:1986;8-11.
2. Daly P.F., Cohen J.S. Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications A review . Cancer Res. 49:1989;770-779.
3. Bottomley P.A. Human in vivo NMR spectroscopy in diagnostic medicine Clinical tool or research probe? Radiology. 170:1989;1-15.
4. Ross B., Marshall V., Smith M., Bartlett S., Freeman D. Monitoring response to chemotherapy of intact human tumors by 31P nuclear magnetic resonance. Lancet. 1:1984;641-646.
5. Steen R.G. Response of solid tumors to chemotherapy monitored by in vivo 31P nuclear magnetic resonance spectroscopy A review . Cancer Res. 49:1989;4075-4085.
6. Segebarth C.M., Baleriaux D.F., Arnold D.L., Luyten P.R., den Hollander J.A. MR image-guided P-31 MR spectroscopy in the evaluation of brain tumor treatment. Radiology. 165:1987;215-219.
7. Vigneron D.B., Hricak H., James T.L., Jajodia P.B., Nunes L., Narayan P. Androgen sensitivity of rat prostate carcinoma studied by 31P NMR spectroscopy, 1H MR imaging, and 23Na MR imaging. Magn. Reson. Med. 11:1989;152-160.
8. Yacoe M.E., Sommer G., Peehl D. In vitro proton spectroscopy of normal and abnormal prostate. Magn. Reson. Med. 19:1991;429-438.
9. Cornel E.B., Smits G.A., Oosterhof G.O., Karthaus H.F., Deburyne F.M., Schalken J.A., Heerschap A. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J. Urol. 150:1993;2019-2024.
10. Schiebler M.L., Miyamoto K.K., White M., Maygarden S.J., Mohler J.L. In vitro high resolution 1H-spectroscopy of the human prostate Benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma . Magn. Reson. Med. 29:1993;285-291.
11. Schick F., Bongers H., Kurz S., Jung W.I., Pfeffer M., Lutz O. Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5 T. Magn. Reson. Med. 29:1993;38-43.
12. Parivar F., Rajanayagan V., Waluch V., Esto R.T., Jones L.W., Ross B.D. Endorectal surface coil MR imaging of prostatic carcinoma with the inversion-recovery sequence. J Magn. Reson. Imaging. 1:1991;657-664.
13. Chelsky M.J., Schnall M.D., Seidmon E.J., Pollack H.M. Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J. Urol. 150:1993;391-395.
14. Narayan P., Vigneron D.B., Jajodia P., Anderson C.M., Hedgcock M.W., Tanagho E.A., James T.L. Transrectal probe for 1H MRI and 31P MR spectroscopy of the prostate gland. Magn. Reson. Med. 11:1989;209-220.
15. Kurhanewicz J., Thomas A., Jajodia P., Weiner M.W., James T.L., Vigneron D.B., Narayan P. 31P spectroscopy of the human prostate gland in vivo using a transrectal probe. Magn. Reson. Med. 22:1991;404-413.
16. Narayan P., Jajodia P., Kurhanewicz J., Thomas A., MacDonald J., Hubesch B., Hedgcock M., Anderson C.M., James T.L., Tanagho E.A., Weiner M.W. Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy A preliminary report . J. Urol. 146:1991;66-74.
17. García-Segura J.M., Sánchez-Chapado M. Espectroscopía por resonancia magnética. Una nueva técnica para el estudio y diagnóstico de la patología prostática. Arch. Esp. Urol. 48:1995;423-446.
18. Kurhanewicz J., Vigneron D.B., Nelson S.J., Hricak H., MacDonald J.M., Konety B., Narayan P. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone Detection via localized proton spectroscopy . Urology. 45:1995;459-466.
19. Parivar F., Hricak H., Shinohara K., Kurhanewicz J., Vigneron D.B., Nelson S.J., Carroll P.R. Detection of locally recurrent prostate cancer after cryosurgery Evaluation by transrectal ultrasound, magnetic resonance imaging and three-dimensional proton magnetic resonance spectroscopy . Urology. 48:1996;594-599.
20. 3) spatial resolution. Radiology. 198:1996;795-805.
21. Kurhanewicz J., Vigneron D.B., Hricak H., Parivar F., Nelson S.J., Shinohara K., Carroll P.R. Prostate cancer Metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopy imaging . Radiology. 200:1996;489-496.
22. Fowler A.H., Pappas A.A., Holder J.C., Finkbeiner A.E., Dalrymple G.V., Mullins M.S., Sprigg J.R., Komoroski R.A. Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR. Magn. Reson. Med. 25:1992;140-147.
23. Merchant T.E., Gierke L.W., Meneses P., Glonek T. 31P magnetic resonance spectroscopic profiles of neoplastic human breast tissues. Cancer Res. 48:1988;5112-5118.
24. Degani H., Horowitz A., Itzchak Y. Breast tumors Evaluation with P-31 MR spectroscopy . Radiology. 161:1986;53-55.
25. Ott D., Hennig J., Ernst T. Human brain tumors Assessment with in vivo proton MR spectroscopy . Radiology. 186:1993;745-752.
26. Frahm J., Bruhn H., Gyngell M.L., Merboldt K.D., Hanicke W., Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes Initial applications to human brain in vivo . Magn. Reson. Med. 9:1989;79-93.
27. McNeal J.E., Kindrachuk R.A., Freiha F.S., Bostwick D.G., Redwine E.A., Stamey T.A. Patterns of progression in prostate cancer. Lancet. 1:1986;60-63.
28. McNeal J.E. Origin and evolution of benign prostatic enlargement. Invest. Urol. 15:1978;340-345.
29. Price H., McNeal J.E., Stamey T.A. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum. Pathol. 21:1990;578-585.
30. Costello L.C., Franklin R.B. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate. 18:1991;25-46.
31. Costello L.C., Franklin R.B. Concepts of citrate production and secretion by prostate. 2. Hormonal relationships in normal and neoplastic prostate. Prostate. 19:1991;181-205.
32. 31P NMR spectroscopy. J. Biol. Chem. 262:1987;14875-14878.
33. Heerschap A., Jager G.J., van der Graaf M., Barentsz J.O., Ruijs S.H.J. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn. Reson. Med. 37:1997;204-213.
34. Lewin L.M., Beer R. Prostatic secretion as a source of myo-inositol in human seminal fluid. Fertil. Steril. 24:1973;666-670.
35. Lynch M.J., Nicholson J.K. Proton MRS of human prostatic fluid Correlations between citrate, spermine, and myo-inositol levels and changes with disease . Prostate. 30:1997;248-255.
36. Berridge M.J. Inositol trisphosphate and diacylglycerol Two interacting second messengers . Annu. Rev. Biochem. 56:1987;159-193.
37. Majerus P.W. Inositol phosphate biochemistry. Annu. Rev. Biochem. 61:1992;225-250.
38. Negendank W., Sauter R. Intratumoral lipids in 1H MRS in vivo in brain tumors Experience of the Siemens cooperative clinical trial . Anticancer Res. 16:1996;1533-1538.
39. Gotsis E.D., Fountas K., Kapsalaki E., Toulas P., Peristeris G., Papadakis N. In vivo proton MR spectroscopy The diagnostic possibilities of lipid resonances in brain tumors . Anticancer Res. 16:1996;1565-1567.
40. Eskew L.A., Bare R.L., McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. Editorial comment by T.A. Stamey. J. Urol. 157:1997;199-203.
41. Lowry M., Liney G.P., Turnbull L.W., Manton D.J., Blackband S.J., Horsman A. Quantification of citrate concentration in the prostate by proton magnetic resonance spectroscopy Zonal and age-related differences . Magn. Reson. Med. 36:1996;352-358.